Diagonal Bio was just listed as a Nasdaq First North Growth Market July 16th. In connection with that, we just wanted to give a short status on where we are on things. Diagonal Bio is a groundbreaking diagnostic company founded during the, you can say, the pandemic. The vision is to limit the spread of infectious disease worldwide by creating an easy-to-use, very accurate, cheap product for testing all different types of infectious disease pathogens. We are not a COVID testing company. We are so much more. Essentially what we are doing is that we are bringing the gold standard of infectious disease testing to the point of care on your patient testing. PANVIRAL is a universal system and means that we can basically adapt the system to any type of infectious disease pathogen, viruses, bacteria, or fungi. I also think if you look back then we have always been one step behind. Every time there's a new disease, we're always one s tep behind in testing. With PANVIRAL, we can actually change that so we can be one step ahead because it's very easy and fast to adapt to new diseases. The revenue will be driven by the sale of consumable, these specific panels. This is where we will generate the revenue. Of course, again, this can be many different areas. We have actually identified three niches that we see a perfect fit with PANVIRAL. The first is something where we see this as a regional specific disease testing, where we will do specific panels, depending on where you live in the world, where you could get tested really quickly for different types of disease or infectious disease pathogens. What you can imagine is that, for example, when we go to the fall, people start to get sick again. We will be able to make a panel with different types of COVID, influenza, maybe respiratory bacteria, and then you could get the result immediately, so within these 10 minutes-15 minutes. Could also be a tropical cocktail or a panel, so if you go somewhere exotic and you come back, you can actually quickly get tested for all of these types of bacteria or viruses or fungi or whatever it is. Again, the system is very adaptable. It can also be used as a state-of-the-art outbreak system. We have very high sensitivity on PANVIRAL, which means that we can essentially detect these infectious disease pathogens before we actually see disease. Governments could use this as a surveillance. Before we actually see a pandemic developing, you will actually have an indication of what's happening in the population. We have this where we see you can use the system for validating treatment at the hospitals. Because of the real-time capabilities of PANVIRAL, you will be able to follow treatments and then also how the infectious disease pathogen will react to different treatment types at the hospitals. Again, many different uses with the platform. First of all, the capital that was raised was actually to ramp up our development activities and also to speed up the implementation of our quality management system and the regulatory processes. We are fully in line with what we have promised in the prospectus so far. I think that the critical points here will be the regulatory processes to make sure we get the approval in time. That will always be the, you can say, the critical point. As also communicated in the Q2 financial report, you can say the milestones for the rest of the year will be that we will deliver more testing on COVID-19 samples. Our quality system will be implemented and up and running, and we will do additional system optimizations. You can say the activities that we have been focusing on so far now is of course that there have been additional focus on product development, but also the quality side and also the regulatory side have had a lot of focus lately.